肝脾联合切除治疗原发性肝癌合并门静脉高压及脾功能亢进

摘要/Abstract

中图分类号:

任家俊, 陈拥军. 肝脾联合切除治疗原发性肝癌合并门静脉高压及脾功能亢进[J]. 外科理论与实践, 2022, 27(02): 139-144.

REN Jiajun, CHEN Yongjun. Simultaneous hepatectomy and splenectomy in treatment of portal hypertension and hypersplenism complicated by primary liver cancer[J]. Journal of Surgery Concepts & Practice, 2022, 27(02): 139-144.

参考文献48

[1]	Sung H, Ferlay J, Siegel R L, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3):209-249. doi:10.3322/caac.21660 URL
[2]	国家卫生健康委办公厅. 原发性肝癌诊疗指南(2022年版)[J]. 中华外科杂志, 2022, 60(4):273-309.
[3]	Xiao H, Zhang B, Mei B, et al. Hepatic resection for hepatocellular carcinoma in patients with portal hypertension: a long-term benefit compared with transarterial chemoembolization and thermal ablation[J]. Medicine (Baltimore), 2015, 94(7):e495. doi:10.1097/MD.0000000000000495 URL
[4]	Forner A, Reig M, Bruix J. Hepatocellular carcinoma[J]. Lancet, 2018, 391(10127):1301-1314. doi:10.1016/S0140-6736(18)30010-2 URL
[5]	Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification[J]. Semin Liver Dis, 1999, 19(3):329-338. doi:10.1055/s-2007-1007122pmid:10518312
[6]	European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma[J]. J Hepatol, 2018, 69(1):182-236. doi:10.1016/j.jhep.2018.03.019 URL
[7]	Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma[J]. Hepatology, 2018, 67(1):358-380. doi:10.1002/hep.29086pmid:28130846
[8]	Lake-Bakaar G, Ahmed M, Evenson A, et al. Management of hepatocellular carcinoma in cirrhotic patients with portal hypertension: relevance of Hagen-Poiseuille′s Law[J]. Liver Cancer, 2014, 3(3-4):428-438. doi:10.1159/000343871pmid:26280004
[9]	Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoem-bolization improves survival[J]. Hepatology, 2003, 37(2): 429-442. doi:10.1053/jhep.2003.50047pmid:12540794
[10]	Bai XM, Cui M, Yang W, et al. The 10-year survival analysis of radiofrequency ablation for solitary hepatocellular carcinoma 5 cm or smaller: primaryversusrecurrent HCC[J]. Radiology, 2021, 300(2):458-469. doi:10.1148/radiol.2021200153 URL
[11]	Kim NH, Lee T, Cho YK, et al. Impact of clinically evident portal hypertension on clinical outcome of patients with hepatocellular carcinoma treated by transarterial chemoembolization[J]. J Gastroenterol Hepatol, 2018, 33(7):1397-1406. doi:10.1111/jgh.14083 URL
[12]	Choi JW, Chung JW, Lee DH, et al. Portal hypertension is associated with poor outcome of transarterial chemoembolization in patients with hepatocellular carcinoma[J]. Eur Radiol, 2018, 28(5):2184-2193. doi:10.1007/s00330-017-5145-9pmid:29218611
[13]	Scheiner B, Ulbrich G, Mandorfer M, et al. Short- and long-term effects of transarterial chemoembolization on portal hypertension in patients with hepatocellular carcinoma[J]. United European Gastroenterol J, 2019, 7(6):850-858. doi:10.1177/2050640619840199 URL
[14]	Zhong JH, Ke Y, Gong WF, et al. Hepatic resection associated with good survival for selected patients with intermediate and advanced-stage hepatocellular carcinoma[J]. Ann Surg, 2014, 260(2):329-340. doi:10.1097/SLA.0000000000000236 URL
[15]	Liu H, Wang ZG, Fu SY, et al. Randomized clinical trial of chemoembolization plus radiofrequency ablationversuspartial hepatectomy for hepatocellular carcinoma within the Milan Criteria[J]. Br J Surg, 2016, 103(4):348-356. doi:10.1002/bjs.10061pmid:26780107
[16]	Oh JH, Sinn DH, Choi GS, et al. Comparison of outcome between liver resection, radiofrequency ablation, and transarterial therapy for multiple small hepatocellular carcinoma within the Milan Criteria[J]. Ann Surg Treat Res, 2020, 99(4):238-246. doi:10.4174/astr.2020.99.4.238 URL
[17]	Harada N, Shirabe K, Maeda T, et al. Comparison of the outcomes of patients with hepatocellular carcinoma and portal hypertension after liver resectionversusradiofrequency ablation[J]. World J Surg, 2016, 40(7):1709-1719. doi:10.1007/s00268-016-3465-6 URL
[18]	Qiu J, Zheng Y, Shen J, et al. Resectionversusablation in hepatitis B virus-related hepatocellular carcinoma patients with portal hypertension: a propensity score mat-ching study[J]. Surgery, 2015, 158(5):1235-1243. doi:10.1016/j.surg.2015.04.002 URL
[19]	陈孝平, 吴在德, 裘法祖. 肝癌切除联合脾切除治疗肝癌合并肝硬化、脾功能亢进[J]. 中华外科杂志, 2005, 43(7):442-446.
[20]	Nagasue N, Kohno H, Tachibana M, et al. Prognostic factors after hepatic resection for hepatocellular carcinoma associated with Child-Turcotte class B and C cirrhosis[J]. Ann Surg, 1999, 229(1):84-90. pmid:9923804
[21]	Oh JW, Ahn SM, Kim KS, et al. The role of splenectomy in patients with hepatocellular carcinoma and secondary hypersplenism[J]. Yonsei Med J, 2003, 44(6):1053-1058. doi:10.3349/ymj.2003.44.6.1053 URL
[22]	Li W, Shen SQ, Wu SM, et al. Simultaneous hepatectomy and splenectomyversushepatectomy alone for hepatocellular carcinoma complicated by hypersplenism: a meta-analysis[J]. Onco Targets Ther, 2015, 8:2129-2137.
[23]	Takeishi K, Kawanaka H, Itoh S, et al. Impact of splenic volume and splenectomy on prognosis of hepatocellular carcinoma within Milan Criteria after curative hepatectomy[J]. World J Surg, 2018, 42(4):1120-1128. doi:10.1007/s00268-017-4232-zpmid:28920178
[24]	Kong J, Shen S, Wang W. Synchronous hepatectomy and splenectomyvs.hepatectomy for selected patients with hepatocellular carcinoma and clinically significant portal hypertension: a systematic review and meta-analysis[J]. J Surg Oncol, 2019, 119(7):964-973. doi:10.1002/jso.25392 URL
[25]	Chen ZL, Yao LQ, Pu JL, et al. Impact of concurrent splenectomy and esophagogastric devascularization on surgical outcomes of partial hepatectomy for hepatocellular carcinoma in patients with clinically significant portal hypertension: a multicenter propensity score matching analysis[J]. Eur J Surg Oncol, 2022, 48(5):1078-1086. doi:10.1016/j.ejso.2021.11.118 URL
[26]	Jiang W, Li Y, Wei W, et al. Spleen contributes to restraint stress induced hepatocellular carcinoma progression[J]. Int Immunopharmacol, 2020, 83:106420.
[27]	Li L, Duan M, Chen W, et al. The spleen in liver cirrhosis: revisiting an old enemy with novel targets[J]. J Transl Med, 2017, 15(1):111. doi:10.1186/s12967-017-1214-8 URL
[28]	Akahoshi T, Hashizume M, Tanoue K, et al. Role of the spleen in liver fibrosis in rats may be mediated by transforming growth factor β-1[J]. J Gastroenterol Hepatol, 2002, 17(1):59-65. doi:10.1046/j.1440-1746.2002.02667.x URL
[29]	Xie XL, Liu X, Ou J. Is synchronous hepatectomy and splenectomy superior to hepatectomy alone for selected patients with hepatocellular carcinoma and clinically significant portal hypertension?[J]. J Surg Oncol, 2019, 120(2):316-317.
[30]	Tsochatzis EA, Senzolo M, Germani G, et al. Systematic review: portal vein thrombosis in cirrhosis[J]. Aliment Pharmacol Ther, 2010, 31(3):366-374. doi:10.1111/j.1365-2036.2009.04182.x URL
[31]	孙勇伟, 罗蒙, 陈炜, 等. 门静脉高压症外科手术后门静脉系统血栓形成[J]. 外科理论与实践, 2006, 11(3):198-200.
[32]	Wu Y, Li H, Zhang T, et al. Splanchnic vein thrombosis in liver cirrhosis after splenectomy or splenic artery embolization: a systematic review and meta-analysis[J]. Adv Ther, 2021, 38(4):1904-1930. doi:10.1007/s12325-021-01652-7 URL
[33]	Rottenstreich A, Kleinstern G, Spectre G, et al. Thromboembolic events following splenectomy: risk factors, prevention, management and outcomes[J]. World J Surg, 2018, 42(3):675-681. doi:10.1007/s00268-017-4185-2pmid:28808782
[34]	Xu L, Qi X, Li H, et al. Prevalence of portal or splenic vein thrombosis in cirrhotic patients after splenectomy: a systematic review and meta-analysis of observational studies[J]. Int J Clin Exp Med, 2016, 9(4):7534-7547.
[35]	张裕, 刘福全. 门静脉系统血栓的抗凝药物选择[J]. 临床肝胆病杂志, 2018, 34(10):2047-2052.
[36]	陈敬宇, 江艺, 张小进. 术前脾切除对肝移植治疗门脉高压症的影响[J]. 中华肝胆外科杂志, 2014, 20(8):572-576.
[37]	许世磊, 刘剑戎, 张英才, 等. 术前脾切除对肝移植术后预后的影响[J]. 中华消化外科杂志, 2018, 17(10):1008-1012
[38]	Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, sta-ging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases[J]. Hepatology, 2018, 68(2):723-750. doi:10.1002/hep.29913pmid:29624699
[39]	Omata M, Cheng AL, Kokudo N, et al. Asia-Pacific cli-nical practice guidelines on the management of hepatocel-lular carcinoma: a 2017 update[J]. Hepatol Int,2017, 11(4):317-370.
[40]	中华医学会外科学分会脾及门静脉高压外科学组. 门静脉高压合并肝癌的临床诊疗专家共识(2022版)[J]. 中华外科杂志, 2022, 60(4):310-320.
[41]	Giannini EG, Savarino V, Farinati F, et al. Influence of clinically significant portal hypertension on survival after hepatic resection for hepatocellular carcinoma in cirrhotic patients[J]. Liver Int, 2013, 33(10):1594-1600. doi:10.1111/liv.12199pmid:23654354
[42]	Midorikawa Y, Takayama T, Higaki T, et al. Selection of patients with esophageal varices for liver resection of hepatocellular carcinoma[J]. Biosci Trends, 2021, 14(6):436-442. doi:10.5582/bst.2020.03329pmid:33055464
[43]	Liu X, Chen Z, Yu M, et al. Safety of simultaneous hepatectomy and splenectomy in the treatment of hepatocellular carcinoma complicated with hypersplenism: a meta-analysis[J]. Gastroenterol Res Pract, 2019, 2019:9065845.
[44]	Zhong JH, Li H, Xiao N, et al. Hepatic resection is safe and effective for patients with hepatocellular carcinoma and portal hypertension[J]. PLoS One, 2014, 9(9):e108755.
[45]	中华医学会外科学分会肝脏外科学组. 肝细胞癌外科治疗方法的选择专家共识(2016年第3次修订)[J]. 中华消化外科杂志, 2017, 16(2):113-115.
[46]	Chen XP, Wu ZD, Huang ZY, et al. Use of hepatectomy and splenectomy to treat hepatocellular carcinoma with cirrhotic hypersplenism[J]. Br J Surg, 2005, 92(3):334-339. doi:10.1002/bjs.4776 URL
[47]	Wu CC, Cheng SB, Ho WM, et al. Appraisal of concomitant splenectomy in liver resection for hepatocellular carcinoma in cirrhotic patients with hypersplenic thrombocytopenia[J]. Surgery, 2004, 136(3):660-668. doi:10.1016/j.surg.2004.01.010 URL
[48]	Sugimachi K, Ikeda Y, Tomikawa M, et al. Appraisal of hepatic resection in the treatment of hepatocellular carcinoma with severe thrombocytopenia[J]. World J Surg, 2008, 32(6):1077-1081. doi:10.1007/s00268-007-9442-3pmid:18338210

肝脾联合切除治疗原发性肝癌合并门静脉高压及脾功能亢进

Simultaneous hepatectomy and splenectomy in treatment of portal hypertension and hypersplenism complicated by primary liver cancer

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献48

相关文章15

编辑推荐

Metrics

本文评价

[1]	叶枫, 龚笑勇, 任家俊, 蔡强, 陈胜.ERCP在原发性肝癌围术期胆道并发症诊治中的应用[J]. 外科理论与实践, 2023, 28(04): 355-360.
[2]	Chang Jessica, 陈旭晓, 陈拥军.脾脏在肝癌合并肝硬化中的临床价值[J]. 外科理论与实践, 2023, 28(04): 394-398.
[3]	张梦茵, 陈平, 袁晓琴, 蔡波尔, 吴云林.内镜下组织黏合剂联合硬化剂注射治疗胃静脉曲张临床研究及随访[J]. 外科理论与实践, 2022, 27(05): 443-447.
[4]	陈晓娟, 张雯, 蔡瑜.经导管脾动脉栓塞术治疗胰源性门静脉高压致消化道出血(附1例报告)[J]. 外科理论与实践, 2022, 27(04): 359-362.
[5]	李涛, 陈皓.肝硬化门静脉高压症的肝移植治疗[J]. 外科理论与实践, 2021, 26(03): 189-194.
[6]	罗蒙, 李泓杰, 郑磊.肝硬化门静脉高压症发病机制的研究现状[J]. 外科理论与实践, 2021, 26(03): 195-198.
[7]	曾宁, 方驰华.数字智能化诊疗技术在门静脉高压症中的应用[J]. 外科理论与实践, 2021, 26(03): 199-202.
[8]	胡明礼, 王绮夏, 马雄.肝硬化食管胃底静脉曲张的药物治疗[J]. 外科理论与实践, 2021, 26(03): 203-207.
[9]	陈炜, 卜俊峰.肝功能评估方式及在门静脉高压症围术期的应用[J]. 外科理论与实践, 2021, 26(03): 212-216.
[10]	杨涛, 阴继凯, 鲁建国.腹腔镜技术在门静脉高压症外科手术中的前景[J]. 外科理论与实践, 2021, 26(03): 217-220.
[11]	崔然, 叶伦河, 王旭菁, 王永坤, 张琪祺, 王恺京, 王明, 戴陈新, 杨鹿笛, 董春秀, 陈波.腹腔镜脾切除联合贲门周围血管离断术治疗肝硬化门静脉高压症的近期临床结果[J]. 外科理论与实践, 2021, 26(03): 221-225.
[12]	张斌, 吴志勇.门静脉高压症食管胃底静脉曲张出血的个体化治疗和手术方式选择[J]. 外科理论与实践, 2021, 26(03): 185-188.
[13]	孙隆慈, 张斌.门静脉海绵样变致食管胃底静脉曲张的手术治疗(附1例报告)[J]. 外科理论与实践, 2021, 26(03): 226-230.
[14]	王丽娟, 潘自来, 苏文婷, 徐敬慈, 饶敏, 刘宵.非对比剂增强磁共振血管成像流入反转恢复序列在肝硬化门静脉高压患者门静脉系统成像的可行性研究[J]. 诊断学理论与实践, 2020, 19(05): 494-498.
[15]	鲍应军, 顾俊鹏, 张海潇, 朱帝文, 任伟新.Viatorr支架与覆膜支架联合裸支架在TIPS治疗门静脉高压症中的疗效对比[J]. 外科理论与实践, 2019, 24(06): 517-521.